|
|
|||||||||||||||||||||
|
|
2003 Fact SheetProstate Cancer: The Public Health Perspective
On this page
A Public Health ConcernProstate cancer is the most common form of cancer, other than skin cancer, among men in the United States, and it is second only to lung cancer as a cause of cancer-related death among men. The American Cancer Society estimates that in 2003, about 220,900 new cases of prostate cancer will be diagnosed and 28,900 men will die of the disease. The Facts*
*Source: American Cancer Society, Cancer Facts and Figures 2003.
What Is Known About the Effectiveness and Benefits of Prostate Cancer Screening?The two most common tests used by physicians to detect prostate cancer are the digital rectal examination (DRE) and the prostate-specific antigen (PSA) test. For the DRE, which has been used for many years, the physician inserts a gloved finger into the rectum to feel for abnormalities. The prostate-specific antigen test is a blood test that measures the PSA enzyme. Although there is good evidence that PSA screening can detect early-stage prostate cancer, evidence is mixed and inconclusive about whether early detection improves health outcomes. In addition, prostate cancer screening is associated with important harms. These include the anxiety and follow-up testing occasioned by frequent false-positive results, as well as the complications that can result from treating prostate cancers that, left untreated, might not affect the patient's health. Since current evidence is insufficient to determine whether the potential benefits of prostate cancer screening outweigh its potential harms, there is no scientific consensus that such screening is beneficial. The position of the Centers for Disease Control and Prevention (CDC) in regard to prostate cancer screening is as follows:
CDC Activities Targeting Prostate CancerWith $14 million allocated to prostate cancer activities in fiscal year 2003, CDC is
These activities will further efforts to develop and deliver appropriate public health strategies for prostate cancer and will improve information sharing between providers and the public relating to screening and treatment alternatives. Examples of these and other CDC activities relating to prostate cancer are highlighted in the sections that follow. Research Supported by CDCDoes Screening Reduce Deaths? Making Informed Decisions About Screening Four projects targeting professional education are being funded in 2003: two at Baylor College of Medicine, one at the University of Texas Health Science Center at San Antonio, and one at the University of California. The purpose is to develop and disseminate educational materials, derived from current evidence, that give primary care professionals the information they need to help their patients make informed decisions about prostate cancer screening. The materials will provide information about screening, factors that influence health outcomes, and options for managing the disease. They will be developed in multiple formats to accommodate differing learning preferences among providers, and Web-based technology will be used to maximize access to and dissemination of the materials. Patterns of Care Patient-Provider Communication Screening Assessment Tools Quality of Life Development of Educational MaterialsCDC is developing a Web-based slide presentation, Screening for Prostate Cancer: Sharing the Decision, to give primary care physicians information on what is and is not known about the potential benefits and side effects of screening for prostate cancer. Physicians will be encouraged to use a shared decision-making approach in helping men decide whether to use screening. The goal is to ensure that men are adequately informed about the issue and are given the opportunity to participate in making this important health care decision. CDC plans to disseminate the slide show in late 2003. CDC has also prepared a decision guide for men who are considering a first-time prostate cancer screening test or who want more information on regular screening. Prostate Cancer Screening: A Decision Guide helps men make informed decisions about screening, by providing them with information about the prostate gland, prostate cancer, and prostate cancer screening, and by encouraging them to discuss screening with their physician or health care provider. The guide can be ordered online at http://www.cdc.gov/cancer/publica.htm. Accompanying materials planned or under development include a two-part video for men, a decision guide for African-American men, and a video and brochure for health care providers. The Association of State and Territorial Chronic Disease Program Directors and its member organizations have received CDC funding to educate state and local policy makers about the complicated issues surrounding prostate cancer screening. The association has developed and released an informational booklet entitled Prostate Cancer Screening: A Matter of Routine or Patient Choice? CDC Partnerships with States and Tribal OrganizationsCDC is providing financial support to help cancer prevention and control programs—operated by state governments and by American Indian/Alaska Native tribal organizations—implement priority activities relating to prostate cancer. Recent examples of these activities include the following:
States receiving CDC funding in 2003 to support their priority prostate cancer activities include Alabama, Alaska, Colorado, Georgia, Michigan, New Mexico, and Utah. CDC and the states recognize that a coordinated, comprehensive approach to cancer prevention and control is essential in order to maximize the impact of limited resources and more readily achieve desired outcomes. *Links to non-Federal organizations found at this site are
provided solely as a service to our users. These links do not constitute an
endorsement of these organizations or their programs by CDC or the Federal
Government, and none should be inferred. The CDC is not responsible for the
content of the individual organization Web pages found at these links. The Role of the Public Health Community in Prostate Cancer ControlIn December 2000, CDC sought advice from approximately 100 experts concerning the role of public health in prostate cancer prevention and control. Those consulted included medical and public health practitioners, researchers, and representatives from community organizations and voluntary associations. They explored the role of public health in relation to risk factors, disease burden, primary and secondary prevention, treatment, and quality of life. Discussions focused on four areas of public health practice: surveillance and monitoring, research, services and programs, and communication. The information that emerged from these sessions continues to help guide CDC and its public health partners in activities relating to prostate cancer. A report summarizing the discussions is available at http://www.cdc.gov/cancer/prostate/prosfuture/index.htm.
You may also download a PDF version (112K) for Adobe Acrobat Reader |